A Safety, Tolerability and Efficacy Study of VRDN 001 in Healthy Volunteers and Persons With Thyroid Eye Disease (TED)
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a
cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R). Inhibition of
IGF-1R may help to reduce the inflammation and associated tissue swelling that occurs in
patients with thyroid eye disease (TED). This clinical trial will evaluate the safety,
tolerability and pharmacokinetics (the concentration of drug in the blood over time) of
VRDN-001 in healthy volunteers and in patients with TED. Study participants with TED will
also be evaluated over time for changes in their signs and symptoms of TED compared to their
baseline measurements.